Data as of Sep 12
| -0.1885 / -0.82%|
Mesoblast Ltd. is engaged in the development of biotherapeutics based on its proprietary cell-based technologies. The company's technology platforms have the potential to deliver a diverse portfolio of clinical-stage products to treat a broad range of conditions with major unmet medical needs. Its products target cardiovascular conditions, diabetes, inflammatory conditions of lungs and joints, eye diseases, bone marrow cancers, bone fractures, cartilage degeneration and musculoskeletal conditions. The company operates through single segment i.e., Research and Development of Adult Mesenchymal Precursor Cells. Mesoblast was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.
|Silviu Itescu||Chief Executive Officer, Executive Director & MD|
|Paul Rennie||Chief Operating Officer|
|Paul Hodgkinson||Chief Financial Officer|
|Donna L. Skerrett||Chief Medical Officer|
|Michael Warman||Executive Vice President-Business Development|